Compare Moderna, Inc. (MRNA) vs Quanta Services Inc (PWR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Quanta Services Inc — how do they compare? Moderna, Inc. trades at $63.7 (market cap $24.18B), while Quanta Services Inc trades at $684.93 (market cap $100.82B). The key difference: Quanta Services Inc is far larger — about 4.2× Moderna, Inc.'s market cap, and Quanta Services Inc pays a 0.07% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | PWR | |
|---|---|---|
Market Cap | $24.18B | $100.82B |
Sector | Health | Industrials |
52-Week High | $81.80 | $785.24 |
52-Week Low | $22.36 | $372.50 |
Enterprise Value | $20.33B | $106.91B |
Dividend Yield | — | 0.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $63.57, up 6.29% on the day, reflecting positive momentum following FDA approval of its mRNA flu vaccine, mFLUSIVA, for adults 50 and older. The stock exhibits a bullish technical outlook with moving averages supporting upward movement, though RSI levels suggest potential overbought conditions. Fundamentally, revenue has declined from pandemic peaks, with 2025 revenue at $1.92B and a net loss of -$2.82B, yet the company has beaten EPS estimates in recent quarters. Cash flow trends show improvement, with net cash flow turning positive in 2025 at $668M.
The outlook for MRNA hinges on pipeline execution beyond COVID-19, with recent vaccine approvals providing growth catalysts. Investment opportunities include diversification into flu, Ebola, and oncology therapies, but risks persist from high cash burn, competitive pressures, and reliance on successful clinical trials. Analyst sentiment is mixed with a consensus price target of $54.33, below the current price, indicating caution despite some bullish developments.
PWR trades at $660.86, down 1.64% over 24 hours, with a neutral technical signal. The company reported strong Q2 2026 earnings, beating estimates with EPS of $4.24 versus $3.31 expected, and raised its full-year 2026 outlook. Revenue growth is robust, reaching $28.48B in 2025, though valuation ratios like a P/E of 76.73 appear elevated. Analyst sentiment is overwhelmingly positive, with 26 buy ratings and a consensus price target of $809.75.
The outlook for PWR is bullish, driven by record backlog and infrastructure demand, but high valuation and negative net cash flow pose risks. Investors face a trade-off between strong growth prospects and premium pricing, with execution on raised guidance being critical for further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Quanta Services Inc
Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two reportable segments: electric power infrastructure solutions and underground utility and infrastructure solutions. In October 2021, the company completed the acquisition of Blattner, a provider of comprehensive engineering, procurement, and construction solutions to customers in the renewable energy industry.
Read more on PWR →
